Metabolic analyses reveal dysregulated NAD+ metabolism and altered mitochondrial state in ulcerative colitis

Yu Hui Kang; Sarah A. Tucker; Silvia F. Quevedo; Aslihan Inal; Joshua R. Korzenik; Marcia C. Haigis

doi:10.1371/journal.pone.0273080

Abstract

Ulcerative colitis (UC) is a complex, multifactorial disease driven by a dysregulated immune response against host commensal microbes. Despite rapid advances in our understanding of host genomics and transcriptomics, the metabolic changes in UC remain poorly understood. We thus sought to investigate distinguishing metabolic features of the UC colon (14 controls and 19 patients). Metabolomics analyses revealed inflammation state as the primary driver of metabolic variation rather than diagnosis, with multiple metabolites differentially regulated between inflamed and uninflamed tissues. Specifically, inflamed tissues were characterized by reduced levels of nicotinamide adenine dinucleotide (NAD⁺) and enhanced levels of nicotinamide (NAM) and adenosine diphosphate ribose (ADPr). The NAD⁺/NAM ratio, which was reduced in inflamed patients, served as an effective classifier for inflammation in UC. Mitochondria were also structurally altered in UC, with UC patient colonocytes displaying reduced mitochondrial density and number. Together, these findings suggest a link between mitochondrial dysfunction, inflammation, and NAD⁺ metabolism in UC.

Citation: Kang YH, Tucker SA, Quevedo SF, Inal A, Korzenik JR, Haigis MC (2022) Metabolic analyses reveal dysregulated NAD⁺ metabolism and altered mitochondrial state in ulcerative colitis. PLoS ONE 17(8): e0273080. https://doi.org/10.1371/journal.pone.0273080

Editor: Jörn Karhausen, Duke University, UNITED STATES

Received: September 7, 2021; Accepted: August 2, 2022; Published: August 17, 2022

Copyright: © 2022 Kang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: As the data contains potentially identifying patient information, data can be made available from the corresponding author or Brigham and Women’s Hospital (IBDResearch@bwh.harvard.edu) upon request.

Funding: Y.H.K. was supported by the Job’s Research Foundation, USA. S.A.T. was supported by a predoctoral T32 fellowship through the Joslin Diabetes Center (DK07260-042). M.C.H. is supported by NCI grant U54-CA225088 and NIDDK grant DK127278. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

The role of mitochondrial function in Inflammatory Bowel Disease (IBD) has become an active area of investigation in recent years, particularly in ulcerative colitis (UC). Several studies have established that mitochondrial dysfunction is a hallmark of IBD pathology [1–3]. The intestinal mucosa in IBD is characterized by hypoxia and increased oxidative stress, and a variety of genes involved in mitochondrial function such as CUL2, LACC1 and NADPH oxidase have been implicated in IBD [4–8]. Suppression of mitochondrial gene expression and function have also been observed in a large UC cohort [2]. However, the mechanism by which dysfunctional mitochondrial metabolism influences IBD pathogenesis remains unclear.

Traditionally perceived as cellular hubs of energy production in the form of adenosine triphosphate (ATP), mitochondria are now recognized as dynamic organelles with diverse roles in regulating metabolism and various cell functions, including apoptosis, production of reactive oxygen species, regulation of gene expression, and modulation of signaling pathways [9–11]. Mitochondrial dysfunction has thus been implicated in multiple metabolic and age-related diseases such as diabetes, cancer, and neurodegenerative disease [12].

In this study we examined changes in mitochondrial morphology in colon tissues from UC patients. Furthermore, we performed metabolomic analysis to identify underlying metabolic alterations in patients with UC that may be linked to mitochondrial dysfunction.

Materials and methods

Study design and sample collection

Colonic biopsies were obtained at colonoscopy with biopsy forceps from individuals with active UC, UC in remission and controls undergoing colonoscopy for colon cancer screening. Tissue biopsies were obtained from the sigmoid region and immediately placed in liquid nitrogen. Signed informed consent was obtained from participants prior to providing samples. Inflammation was determined by histologic assessment by a pathologist. Activity within the disease cohort was defined as inflammation in any part of the colon as determined by pathology. All research in this study involving human participants has been approved under the Mass General Brigham IRB (Protocol #2010P002317).

Metabolomics–Sample preparation

Colonic biopsies (1–15 mg) were snap frozen and metabolites extracted by methanol-chloroform extraction. Briefly, tissues were resuspended in 600 μl of 60% methanol and 400 μl of chloroform. All solvents used during sample preparation were of LC-MS-grade quality. 2 stainless steel beads were added and the tissues homogenized using a TissueLyser LT (Qiagen) for 2 min at 50 Hz. The extracts were centrifuged at 13.3 krpm, 4°C for 15 min and the aqueous layer dried in a SpeedVac. The dried extracts were then reconstituted in 1:1 acetonitrile-water for analysis on the MS.

Samples were run on a Vanquish UHPLC system (Thermo Fisher) coupled to a Q-Exactive HF-X mass spectrometer utilizing a HESI probe (Thermo Fisher) on both positive and negative ion modes. For the LC, hydrophilic interaction liquid chromatography (HILIC) was used, specifically a 150 X 2.1 mm iHILIC®-(P) Classic polymeric column equipped with a 2.1 x 20 mm iHILIC®-(P) Classic Guard column (both 5 μm, 200 Å, HILICON AB). Buffers A (20 mM ammonium carbonate in water, with 0.1% ammonium hydroxide for negative mode or formic acid to pH 6.8 for positive mode) and B (100% acetonitrile) were used. A linear gradient was performed at a flow rate of 0.15 ml/min as follows: 80% to 20% Buffer B linear gradient from 0–20 min, 20% to 80% Buffer B linear gradient from 20–20.5 min, hold at 80% Buffer B from 20.5–28 min, hold at 80% Buffer B from 28–30 min without data acquisition. The column was held at 25°C, the column preheater at 30°C and the autosampler at 10°C. MS acquisition was performed on full scan mode over a range of 70–1000 m/z and a resolution of 60,000, an AGC target of 1e5 and a maximum injection time of 20 ms with a 5 eV in-source CID. The spray voltage was set to 3.9 kV (positive) or 3 kV (negative), the heated capillary was set at 275°C and the probe set at 325°C (positive) or 350°C (negative). The sheath gas flow rate was 40, the auxiliary gas was set at 10 (positive) or 15 (negative) and the sweep gas flow rate set to 1.

Metabolomics–data analysis

Feature extraction and peak integration was performed using Tracefinder version 4.1 (Thermo Fisher). Metabolites were identified using exact mass with a 5 ppm tolerance and retention time with reference to an in-house library of chemical standards. Allowed species were [M+H]⁺ for positive mode and [M-H]^- for negative mode. Peaks were manually curated to exclude low quality peaks (e.g. noise, multiple peaks) and metabolites with no identified peaks. For metabolites detected in both modes, the peaks in negative mode were selected. Based on these criteria, 75 metabolites were consistently detected across both experiments and the peak areas used for further analysis on RStudio IDE and Graphpad Prism.

Data processing was performed for each experiment in each mode using code derived from Metaboanalyst [13]. For univariate analyses (single metabolite comparisons, volcano plot), the areas were normalized to a constant sum (1000).

For multivariate analyses (PCA, Pathway analysis), constant sum normalization was performed and metabolites with constant values removed. Missing or zero values were replaced with half of the minimum positive value. The values were then glog transformed () and autoscaled. Data for both experiments were then combined and autoscaled to account for experiment-to-experiment variation and rescaled after outlier removal. Pathway analysis was performed using metPA based on a global test, with node importance assessed by relative betweenness centrality [14].

Statistical significance was assessed using the Mann-Whitney test with p value < 0.05 considered as significant.

The following R packages were used for these analyses: tidyverse, rstatix, EnhancedVolcano, PCAtools, factoextra, RColorBrewer, Hmisc, corrplot.

Mitochondrial electron microscopy–sample preparation, data collection, and analysis

Colonic biopsies (cut into 1–2 mm cubes) provided by the Crohn’s and Colitis Center at Brigham and Women’s Hospital were fixed with 0.1 M cacodylate buffer, pH 7.4, containing 2.5% glutaraldehyde and 2% paraformaldehyde, and stored at 4°C for up to 2 weeks prior to further processing. Fixed samples were submitted to the Harvard Medical School Electron Microscopy Facility for embedding, sectioning, and staining. Imaging was done using a Tecnai G² Spirit BioTWIN Transmission Electron Microscope equipped with an AMT 2k CCD camera. 30–40 electron micrographs were taken per patient sample at three different magnifications, 1200x, 4800x, and 9600x.

For a given biopsy, 1200x images were used to define areas where colonocytes were present, and 4800x and 9600x images were used to quantify mitochondrial features of interest. Fiji software was used to identify individual mitochondria and determine their features, including area and roundness (approximated by mitochondrial ratio of length to width). When calculating total area in biopsy tissue occupied by mitochondria, the area of any lumen included in the defined analysis area was subtracted to obtain the sample area to ensure our calculations reflected only biopsy tissue area. All analysis was performed blinded to which samples were from controls versus UC patients. Graphpad Prism was used for statistical analyses. Statistical significance was assessed using the Mann-Whitney test with p value < 0.05 considered as significant. Values of technical replicates were averaged for each sample prior to statistical analysis.

Results

To assess the metabolic differences that might drive mitochondrial dysfunction in UC, we collected biopsies from the sigmoid colon of controls (n = 14) and UC patients (n = 19) and subjected them to mitochondrial electron microscopy and metabolomics analysis (Fig 1A). The characteristics of these patients are summarized (Table 1 and S1A Fig). 11 of the 19 UC patients, 7 of whom were in remission (i.e. inactive), had biopsies taken from uninflamed regions of the colon (Table 1). 8 patients, all of whom had active UC, had samples collected from inflamed regions of the colon (Table 1). We note that the control group was significantly older than UC patients with inflamed tissue as these control biopsies were collected as part of routine colon screenings (Table 1).

Download:

Fig 1. Metabolomic profiles of intestinal tissue cluster primarily by inflammation rather than diagnosis.

(A) Schematic of experimental design. Created with Biorender. Colonic tissue biopsies were subjected to metabolomic analysis across 2 independent experiments or mitochondrial structure analysis by electron microscopy. (B) Pearson correlation analysis of PCs and various metadata, with * p<0.05, **p<0.01, ***p<0.001 (C-D) Principal component analysis (PC1 vs PC2) of metabolomic data comparing (C) Control vs UC biopsies or (D) control vs UC biopsies further stratified by inflammation state. (E) Volcano plot of metabolites differentially regulated in uninflamed (control + UC) vs inflamed UC tissues, plotting log₂(inflamed/uninflamed) vs -log₁₀(P) value as assessed by Mann-Whitney test.

https://doi.org/10.1371/journal.pone.0273080.g001

Download:

Table 1. Patient demographics showing their age (mean ± S.D.), gender, BMI (mean ± S.D.), biopsy location, duration of disease (mean ± S.D.), disease activity, and extent of disease (mean ± S.D.).

Activity refers to the presence of inflammation in any region of the colon and is not restricted to the site of the tissue biopsy, while inflammation refers specifically to the site of the tissue biopsy. ***p<0.001 by Kruskal-Wallis test with Dunn’s correction for multiple comparisons.

https://doi.org/10.1371/journal.pone.0273080.t001

Intestinal metabolomic profiles cluster primarily by inflammation state

To gain insight into the metabolic state of human UC, biopsies of colon tissues from UC patients were subjected to metabolic profiling across 2 independent experiments. Using a semi-targeted approach, we consistently detected 75 metabolites, whose intensities were normalized to a constant sum as the sum of raw intensities correlated with the initial weight of the biopsy (S1B Fig). Initial principal component analysis (PCA) attributed most variation to 1 sample, hence this outlier was removed in subsequent analyses (S1C Fig).

We first analyzed what clinical factors might drive the metabolic differences by performing a correlation analysis between the principal components (PC) and various clinical parameters (Fig 1B). Focusing on PC1-2, which captured most (~38.1%) of the variation, we observed no statistically significant correlation between the PCs and the parameter “diagnosis”, which is defined as whether subjects were control or UC patients (Figs 1B and S1D). This finding was supported by the degree of overlap between controls and UC patients on the PCA plot (Fig 1C). Interestingly, the metabolite profiles correlated significantly with the parameter “Inflammation”, which is the inflammation state of the tissue (Fig 1B). Indeed, inflamed colon tissues formed a distinct cluster from controls and patients with uninflamed tissues (Fig 1D). Similar results were observed with regard to activity status (Figs 1B and S1E).

Together, these data suggest that inflammation, rather than UC diagnosis, was the primary driver of metabolic differences.

NAD⁺ metabolism is dysregulated in inflamed tissue

We next sought to understand the metabolites driving these differences. As the metabolic profiles of control and uninflamed patient tissues were similar (Fig 1D), these groups were combined for differential analysis, revealing several significantly altered metabolites between inflamed and uninflamed tissue (Figs 1E and S2A–S2O).

Pathway analysis revealed “nicotinate and nicotinamide metabolism” as the top regulated pathway distinguishing inflamed tissues from uninflamed tissues (Fig 2A). NAD⁺ is a critical metabolite that not only harvests energy from catabolic processes but also serves as a cofactor for multiple metabolic enzymes [15]. NAD⁺ can be degraded by multiple enzymes (SIRTs, PARPs, CD38, CD157) to generate NAM and ADPr or its variants (2/3’-O-acyl-ADPr, poly(ADPr), cyclic-ADPr) depending on the enzyme [15]. NAD⁺ can be synthesized via various pathways—either from NAM, nicotinamide riboside (salvage pathway), tryptophan (de novo pathway) or from nicotinic acid (Preiss-Handler pathway) [16] (Fig 2B).

Download:

Fig 2. Pathway analysis identifies dysregulation of NAD⁺ metabolism in inflamed UC tissue.

(A) Metabolic pathway (MetPA) analysis of pathways differentially regulated in uninflamed (control + UC) vs inflamed UC colon tissue biopsies, with top significant pathways indicated. (B) NAD⁺ metabolism pathways, with differentially regulated metabolites color-coded (p<0.05, Mann-Whitney test). (C)–(E) Normalized abundance of (C) NAD⁺ and its degradation products (D) NAM and (E) ADPr indicated, analyzed by Mann-Whitney test. Graphs depict mean ± SEM. **p<0.01, ***p<0.001. NAD⁺—Nicotinamide adenine dinucleotide, NAM—Nicotinamide, ADPr–ADP ribose, NA–Nicotinic Acid, NR—nicotinamide riboside, NAMN- nicotinic acid mononucleotide, NAAD—nicotinic acid adenine dinucleotide, NMN—nicotinamide mononucleotide, QA–Quinolinic acid, NMNAT- nicotinamide mononucleotide adenylyltransferase, NAPRT–nicotinate phosphoribosyltransferase, NADS—NAD synthetase, NRK–Nicotinamide riboside kinase, SIRT–Sirtuins, PARP–Poly(ADP-ribose) polymerase, NAMPT—Nicotinamide phosphoribosyltransferase, PncA–Nicotinamidase.

https://doi.org/10.1371/journal.pone.0273080.g002

Consistent with the pathway analysis, we observed that inflamed tissues displayed reduced levels of NAD⁺ (Fig 2C) and elevated levels of the corresponding metabolic by-products NAM (Fig 2D) and ADPr (Fig 2E). Within uninflamed tissues, control and UC uninflamed tissues displayed no differences in these metabolites, while inflamed tissues displayed reduced NAD⁺ compared to control and UC uninflamed tissues and elevated NAM and ADPr compared to controls (S3A–S3C Fig). Together, these data are consistent with the idea that that NAD⁺ degradation or recycling is altered during intestinal inflammation.

Our PC correlation analysis also revealed associations between PC3/PC4 and several clinical parameters (Fig 1B), although these contributed less to overall metabolic variance (S1D Fig). In agreement with this analysis, we observed distinct clusters on PC3/4 according to diagnosis (S4A Fig), inflammation (S4B Fig), activity (S4C Fig) and age (S4D Fig). To distinguish which metabolites might be driving the separations in PCA, we analyzed the loadings (top/bottom 5% of variables) for each PC. Focusing on PC3-4, loadings analysis revealed several metabolites (including NAM), suggesting that these metabolites might be associated with the clinical parameters (S4E Fig). However, it is difficult to distinguish whether these metabolites are associated with one or several parameters. This is further complicated by the association of these parameters with one another as a result of disease biology (inflamed tissues are all from active UC patients) or experimental design (controls undergoing colonoscopy will typically be of older age) (S4F Fig). We analyzed the loadings for PC1, the component associated with inflammation and activity only, as well as PC2 (Fig 1B). This analysis revealed NAD⁺ to be negatively associated with PC1 (S4G Fig). Therefore, the depletion of NAD⁺ is likely to be a feature specific to disease pathogenesis.

Intestinal NAD⁺/NAM ratios predict inflammation but not diagnosis

Consistent with NAM being a product of NAD⁺ degradation, we observed that NAD⁺ levels inversely correlated with NAM levels (Fig 3A). We thus hypothesized that the NAD⁺/NAM ratio, which was reduced in inflamed tissues as expected (Fig 3B), might predict inflammation state in the intestine.

Download:

Fig 3. Intestinal NAD⁺/NAM ratios predict inflammation but not diagnosis.

(A) Pearson correlation analysis of normalized NAD⁺ vs NAM levels in various disease states. (B) Comparison of NAD⁺/NAM ratios in inflamed vs uninflamed (control + UC) tissues. Graph depicts mean ± SEM, *** p<0.001 by Mann-Whitney test. (C-G) Receiver operating characteristic (ROC) analysis of the ability of colon biopsy NAD⁺/NAM ratio to predict various disease states, with area under the curve (AUC) and p values shown. Specifically, they show the ability of NAD⁺/NAM ratios to distinguish (C) diagnosis, (D) inflammation state, (E) control vs uninflamed UC tissue, (F) control vs inflamed UC tissue and (G) inflamed vs uninflamed UC tissue.

https://doi.org/10.1371/journal.pone.0273080.g003

Receiver operating characteristic (ROC) analysis revealed that NAD⁺/NAM ratio could discriminate based on colon tissue inflammation but could not distinguish controls from UC patients (Fig 3C and 3D). We also observed that, within uninflamed tissues, the NAD⁺/NAM ratio could not discriminate between control and UC samples (Fig 3E). However, inflamed tissues from UC patients could be discriminated from control or uninflamed UC samples (Fig 3F and 3G). Together, these data suggest that the NAD⁺/NAM ratio can be used as a predictor of inflammation in UC.

UC patients display altered mitochondrial morphology in the intestine

Defects in NAD⁺ metabolism have been implicated in mitochondrial dysfunction [16]. We hypothesized that mitochondrial dysfunction might be a distinguishing feature of IBD.

To test this idea, we assessed mitochondrial morphology in the colonic tissue of controls and UC patients by electron microscopy (EM). Most of these samples were from patients who contributed tissues for metabolomics analysis (metadata in S1 Table). We observed striking differences in mitochondrial number and morphology in colonocytes from UC patients (Fig 4A). Quantification analyses revealed a significant reduction in mitochondrial density and number (Fig 4B and 4C), indicative of mitochondrial dysfunction. These differences tended to be more pronounced in inflamed UC tissues compared to uninflamed UC tissues, but more samples will be required to validate these differences (Fig 4B and 4C). We did not observe significant differences in the size or roundness of individual mitochondria (Fig 4D and 4E). Similar differences were also observed when comparing uninflamed (control + UC uninflamed) with inflamed samples (S5 Fig).Together, these suggest a potential role for mitochondrial dysfunction in IBD pathogenesis.

Download:

Fig 4. Mitochondrial abnormalities in UC patients.

(A) Representative EM micrographs of colon biopsy tissue from controls and UC patients, with a scale bar of 1 μm. Rectangle indicates region represented in lower panels, with a scale bar of 600 nm. Arrows indicate individual mitochondria. (B-E) Quantitation of the EM micrographs (n = 4 images per sample, 5–8 samples per group) showing changes in (B) the percent area occupied by the mitochondria between groups and (C) the number of mitochondria per 100 μm² area, with no significant changes in (D) single mitochondrial area or (E) the roundness of mitochondria. Graphs depict mean ± SEM, *p<0.05 by Mann-Whitney test. Each point denotes the average of technical replicates for one control/patient.

https://doi.org/10.1371/journal.pone.0273080.g004

Discussion

It is increasingly appreciated that metabolic alterations play a key role in shaping the pathogenesis of IBD and can serve as useful biomarkers [17, 18]. Although metabolomics have been performed in earlier IBD studies yielding useful insights, most of these studies were run on biofluids (stool, urine, blood) [19–23] and it is unclear whether these changes can be translated to the gut. We performed metabolomics in the UC colon and show that NAD⁺ depletion is a key feature of UC patients with active colonic inflammation. NAD⁺ depletion is a hallmark of aging and aging-related metabolic diseases such as fatty liver disease, diabetic nephropathy, and neurodegenerative disorders [15]. Our study adds IBD, specifically UC, to this list of diseases [24, 25]. Furthermore, the specificity of NAD⁺ depletion for inflamed tissues suggests that it might play an important role in regulating disease outcome.

We provide evidence that the NAD⁺ depletion likely stems from enhanced NAD⁺ degradation, as we also observed an increase in NAM and ADPr—key metabolic products of NAD⁺ catabolism—in inflamed UC. While elevations in NAM levels have been observed in active UC [26], the source of this increase was not explored. Of the enzymes involved in NAD⁺ catabolism (SIRTs, PARPs, CD38, CD157), CD38 is an attractive target for further investigation as it can directly generate NAM and ADPr from NAD⁺ [27, 28]. Upregulation of CD38 has been reported in human IBD, specifically in inflamed tissues [29]. Moreover, Cd38^-/- mice display milder colitis, suggesting that the upregulation of this molecule is pathogenic in IBD and that therapeutic modalities targeting CD38 in cancer and aging might also be relevant for this disease [30–32]. However, we do not exclude the possibility that ADPr might be derived from further breakdown of 2/3’-O-acyl-ADPr produced by SIRT activity and/or poly(ADPr) produced by PARP activity [33]. Further studies assessing the roles of these pathways in the UC colon will be important for defining the pathways involved in UC.

It has been reported that UC patients display reduced expression of multiple mitochondrial genes [2], but it is currently unclear how this translates to differences in mitochondrial structure. In agreement with a previous study, we observed significant morphological alterations in UC tissue along with reduced mitochondrial numbers, with possible further stratification by inflammation state [3]. These abnormalities point to severe mitochondrial dysfunction and contribute to our understanding of UC as a possible mitochondriopathy. As mitochondria are the site of oxygen-consuming processes such as oxidative phosphorylation [9], reductions in mitochondrial number might be postulated to increase oxygen levels in the gut, leading to alterations in the intestinal microbiota to favor facultative anaerobes and the development of dysbiosis [34, 35].

Our data points to dysregulated NAD⁺ metabolism and altered mitochondrial morphology as possible features of UC. However, they do not reveal a causal relationship between these features in the context of UC i.e. whether reduced NAD⁺/NAM ratio drives alterations in mitochondrial morphology, vice versa or both. Reductions in NAD⁺ levels have been associated with multiple contexts such as aging, neurodegeneration and metabolic disease [36]. Importantly, enhancement of NAD⁺ levels through provision of NAD⁺ precursors and targeting of specific enzymes involved in NAD⁺ biosynthesis/degradation has been shown to reverse several of these pathologies including mitochondrial dysfunction, pointing to a causal role of NAD⁺ metabolism in regulating these processes [15, 37].

One of the key ways by which NAD⁺ levels regulate mitochondrial metabolism is its effect on sirtuins, a family NAD⁺-consuming protein deacylases [36]. Reductions in NAD⁺ levels lead to reduced activities of SIRT1 and SIRT3, resulting in reduced mitochondrial biogenesis and altered mitochondrial morphology (for SIRT1) as well as mitochondrial protein hyperacetylation (for SIRT3) [38–41]. Patients with PARP1 hyperactivation also show reduced levels of mitophagy due to defective SIRT1 activity [42]. It is thus possible that reductions in NAD⁺ levels lead to alterations in mitochondrial morphology in a sirtuin-dependent manner.

However, the converse (mitochondrial dysfunction driving NAD⁺ depletion) can also occur. The reduced form of NAD⁺—NADH—serves as an important carrier of metabolic energy to complex I of the mitochondrial electron transport chain (ETC), where it is oxidized back to NAD⁺ [15]. Deletion of complex I has been reported to reduce the NAD⁺/NADH ratio, subsequently impairing SIRT3 activity [39]. Therefore, the overall picture is likely complex, whereby mitochondrial state and NAD⁺ metabolism are closely intertwined and can mutually affect each other. A mechanistic understanding of this relationship in suitable in vitro or in vivo models would thus be important in understanding the contribution of these features to UC.

In IBD, the role of NAD⁺ metabolism in disease pathogenesis is unclear [15]. NAMPT, the rate limiting enzyme of the NAD salvage pathway, is upregulated in IBD [43, 44]. Blockade of NAMPT ameliorated experimental colitis, suggesting this pathway as a potential therapeutic target [24, 25]. Interestingly, treatment with the NAMPT inhibitor FK866 did not affect levels of ATP but rather the activities of NAD⁺-catabolizing enzymes such as PARP1, SIRT6 and CD38 [24]. As mentioned above, CD38 activity is potentially pathogenic in IBD [30]. PARP1 and PARP2 have also been documented to promote colitis in mice [45, 46]. However, the roles of the SIRTs are not straightforward and sometimes contradictory. While multiple sirtuins (SIRT1,2,3,5,6) have been reported to exhibit protective effects on IBD [47–52], other sirtuins (SIRT1) can be pathogenic [53]. Together, the findings from our study and others support the need for further investigation of NAD⁺ metabolism in IBD.

Our study raises several interesting avenues for further investigation. Although our sample size was sufficient to pick out certain interesting metabolic phenotypes, further studies in a larger cohort will be needed to ascertain if these findings can encompass the heterogeneity of human UC [18]. It will also be interesting to investigate the relevance of NAD⁺ depletion to Crohn’s disease. We also note that these patients received various treatments, thus further studies focused on treatment-naïve patients will be helpful in discovering additional relevant metabolic pathways, particularly in the context of early disease. Further characterization of other metabolites in NAD⁺ metabolic pathways (e.g. ADPr derivatives, intermediates of NAD⁺ biosynthesis) will be critical in understanding the extent by which NAD⁺ metabolism is dysregulated in UC. Finally, it will be interesting to identify potential regulators of mitochondrial function in IBD, such as PGC-1α which can be regulated by NAD⁺ availability, and to understand how these regulators might also modulate intestinal inflammation [54].

In conclusion, we show that the colonic environment in human UC is marked by dysregulated metabolism and mitochondrial morphology. The altered metabolism is specific to UC patients displaying active inflammation and can be distinguished by a reduced NAD⁺/NAM ratio. We further show that UC tissues display altered mitochondrial morphology. Together, these suggest that NAD⁺ metabolism might be an attractive therapeutic pathway for targeting colonic inflammation.

Supporting information

S1 Fig.

Additional metadata and further initial metabolomic analyses (A) Table showing treatment demographics of control and UC patients. (B) Pearson correlation analysis of the sum of all metabolite intensities for each mode vs initial weight of biopsy in all samples including outlier. (C) PCA analysis of all samples with outlier included. (D) Scree plot of PCA analysis as in Fig 1B–1D. (E) PCA analysis as in Fig 1C and 1D, but stratified by activity. Inactive patients included all controls as well as UC patients in remission. ^† indicates patient was taking sulfasalazine (not a 5-ASA but often considered one) for arthritis.

https://doi.org/10.1371/journal.pone.0273080.s001

(TIF)

S2 Fig. Graphs of other metabolites differentially regulated as in Fig 1E but not shown in Fig 2C–2E.

Graphs depict mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 analyzed by Mann-Whitney test.

https://doi.org/10.1371/journal.pone.0273080.s002

(TIF)

S3 Fig. NAD, NAM and ADPr from Fig 2C–2E, with further separation of uninflamed samples into controls and UC uninflamed.

Normalized abundance of (A) NAD⁺ and its degradation products (B) NAM and (C) ADPr indicated. Graphs depict mean ± SEM. *p<0.05, **p<0.01 by Kruskal-Wallis Test with Dunn’s correction for multiple comparisons.

https://doi.org/10.1371/journal.pone.0273080.s003

(TIF)

S4 Fig. PCA Analyses focusing on PC3 and PC4.

(A-D) Principal component analysis (PC3 vs PC4) of metabolomic data comparing (A) Control vs UC biopsies, (B) uninflamed (control + UC uninflamed) vs inflamed biopsies, (C) Active vs Inactive (control + UC in remission) or (D) all samples stratified by age. (E) Loadings plot of PC3 and PC4 showing metabolites in top/bottom 5% of the loadings range for each PC. (F) Spearman correlation coefficients of the different clinical parameters (excluding outlier) performed using Hmisc R package and visualized the corrplot R package, with values having p>0.05 removed and ordered by hierarchical clustering. (G) Loadings plot as in (F), but for PC1 and PC2.

https://doi.org/10.1371/journal.pone.0273080.s004

(TIF)

S5 Fig. Quantitation of the EM micrographs as in Fig 4, but with samples stratified by inflammation.

Uninflamed represent control + UC uninflamed. Graphs show (A) changes in the percent area occupied by the mitochondria between groups and (B) the number of mitochondria per 100 μm² area, with no significant changes in (C) single mitochondrial area or (D) the roundness of mitochondria. Graphs depict mean ± SEM, *p<0.05 by Mann-Whitney test. Each point denotes the average of technical replicates for one control/patient.

https://doi.org/10.1371/journal.pone.0273080.s005

(TIF)

S1 Table. Patient demographics for the EM study, showing age (mean ± S.D.), gender, BMI (mean ± S.D.), biopsy location, duration of disease (mean ± S.D.), disease activity, extent of disease (mean ± S.D.), and treatment demographics.

**p<0.01 by Mann-Whitney test. † indicates patient was taking sulfasalazine (not a 5-ASA but often considered one) for arthritis.

https://doi.org/10.1371/journal.pone.0273080.s006

(TIF)

Acknowledgments

We thank the Resnek Family for their generous support of this project through the Resnek Family Center for PSC Research at Brigham and Women’s Hospital.

We are grateful to the Crohn’s and Colitis Center at Brigham and Women’s Hospital for provision and processing of clinical samples. We thank the Harvard Medical School Electron Microscopy Facility for assistance with the EM experiments. We thank Silvia F Quevedo for assistance in coordinating the provision of clinical samples and metadata. We thank Shakchhi Joshi for assistance with sample preparation and maintenance of the mass spectrometers, and Jonah Wyett for assistance with the EM experiments. We are also grateful to members of the Haigis lab and the Korzenik lab for their input throughout the project.

References

1. Roediger WEW. The Colonic Epithelium in Ulcerative Colitis: an Energy-Deficiency Disease? Lancet. 1980;316: 712–715.
- View Article
- Google Scholar
2. Haberman Y, Karns R, Dexheimer PJ, Schirmer M, Somekh J, Jurickova I, et al. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun. 2019;10. pmid:30604764
- View Article
- PubMed/NCBI
- Google Scholar
3. Smith SA, Ogawa SA, Chau L, Whelan KA, Hamilton KE, Chen J, et al. Mitochondrial dysfunction in inflammatory bowel disease alters intestinal epithelial metabolism of hepatic acylcarnitines. J Clin Invest. 2021;131. pmid:33141762
- View Article
- PubMed/NCBI
- Google Scholar
4. Graham DB, Xavier RJ. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature. Springer US; 2020. pp. 527–539. pmid:32103191
- View Article
- PubMed/NCBI
- Google Scholar
5. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491: 119–124. pmid:23128233
- View Article
- PubMed/NCBI
- Google Scholar
6. Lahiri A, Hedl M, Yan J, Abraham C. Human LACC1 increases innate receptor-induced responses and a LACC1 disease-risk variant modulates these outcomes. Nat Commun. 2017;8: 1–13. pmid:28593945
- View Article
- PubMed/NCBI
- Google Scholar
7. Muise AM, Xu W, Guo CH, Walters TD, Wolters VM, Fattouh R, et al. NADPH oxidase complex and IBD candidate gene studies: Identification of a rare variant in NCF2 that results in reduced binding to RAC2. Gut. 2012;61: 1028–1035. pmid:21900546
- View Article
- PubMed/NCBI
- Google Scholar
8. Rivas MA, Beaudoin M, Gardet A, Stevens C, Sharma Y, Zhang CK, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet. 2011;43: 1066–1073. pmid:21983784
- View Article
- PubMed/NCBI
- Google Scholar
9. Mishra P, Chan DC. Metabolic regulation of mitochondrial dynamics. J Cell Biol. 2016;212: 379–387. pmid:26858267
- View Article
- PubMed/NCBI
- Google Scholar
10. Mehta MM, Weinberg SE, Chandel NS. Mitochondrial control of immunity: Beyond ATP. Nat Rev Immunol. 2017;17: 608–620. pmid:28669986
- View Article
- PubMed/NCBI
- Google Scholar
11. Srivastava S. Emerging therapeutic roles for NAD + metabolism in mitochondrial and age-related disorders. Clin Transl Med. 2016;5: 25. pmid:27465020
- View Article
- PubMed/NCBI
- Google Scholar
12. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu Rev Genet. 2005;39: 359–407. pmid:16285865
- View Article
- PubMed/NCBI
- Google Scholar
13. Pang Z, Chong J, Li S, Xia J. Metaboanalystr 3.0: Toward an optimized workflow for global metabolomics. Metabolites. 2020;10. pmid:32392884
- View Article
- PubMed/NCBI
- Google Scholar
14. Xia J, Wishart DS, Valencia A. MetPA: A web-based metabolomics tool for pathway analysis and visualization. Bioinformatics. 2011;27: 2342–2344. pmid:20628077
- View Article
- PubMed/NCBI
- Google Scholar
15. Katsyuba E, Romani M, Hofer D, Auwerx J. NAD+ homeostasis in health and disease. Nature Metabolism. Springer US; 2020. pp. 9–31. pmid:32694684
- View Article
- PubMed/NCBI
- Google Scholar
16. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science (80-). 2015;350: 1208–1213. pmid:26785480
- View Article
- PubMed/NCBI
- Google Scholar
17. Kumar M, Garand M, Al Khodor S. Integrating omics for a better understanding of Inflammatory Bowel Disease: A step towards personalized medicine. J Transl Med. 2019;17: 1–13. pmid:31836022
- View Article
- PubMed/NCBI
- Google Scholar
18. De Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: An integrated view of aetiology, pathogenesis and therapy. Nature Reviews Gastroenterology and Hepatology. 2017. pp. 739–749. pmid:28831186
- View Article
- PubMed/NCBI
- Google Scholar
19. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4: 293–305. pmid:30531976
- View Article
- PubMed/NCBI
- Google Scholar
20. Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569: 655–662. pmid:31142855
- View Article
- PubMed/NCBI
- Google Scholar
21. Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V. Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017;11: 321–334. pmid:27609529
- View Article
- PubMed/NCBI
- Google Scholar
22. Jansson J, Willing B, Lucio M, Fekete A, Dicksved J, Halfvarson J, et al. Metabolomics Reveals Metabolic Biomarkers of Crohn’s Disease. PLoS One. 2009;4: e6386. pmid:19636438
- View Article
- PubMed/NCBI
- Google Scholar
23. Daniluk U, Daniluk J, Kucharski R, Kowalczyk T, Pietrowska K, Samczuk P, et al. Untargeted metabolomics and inflammatory markers profiling in children with Crohn’s disease and ulcerative colitis—A preliminary study. Inflamm Bowel Dis. 2019;25: 1120–1128. pmid:30772902
- View Article
- PubMed/NCBI
- Google Scholar
24. Gerner RR, Klepsch V, Macheiner S, Arnhard K, Adolph TE, Grander C, et al. NAD metabolism fuels human and mouse intestinal inflammation. Gut. 2018;67: 1813–1823. pmid:28877980
- View Article
- PubMed/NCBI
- Google Scholar
25. Colombo G, Clemente N, Zito A, Bracci C, Colombo FS, Sangaletti S, et al. Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. J Mol Med. 2020;98: 595–612. pmid:32338310
- View Article
- PubMed/NCBI
- Google Scholar
26. Diab J, Hansen T, Goll R, Stenlund H, Jensen E, Moritz T, et al. Mucosal metabolomic profiling and pathway analysis reveal the metabolic signature of ulcerative colitis. Metabolites. 2019;9: 1–15. pmid:31783598
- View Article
- PubMed/NCBI
- Google Scholar
27. Hogan KA, Chini CCS, Chini EN. The Multi-faceted Ecto-enzyme CD38: Roles in immunomodulation, cancer, aging, and metabolic diseases. Front Immunol. 2019;10: 1–12. pmid:31214171
- View Article
- PubMed/NCBI
- Google Scholar
28. Zocchi E, Franco L, Guida L, Benatti U, Bargellesi A, Malavasi F, et al. A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. Biochem Biophys Res Commun. 1993;196: 1459–1465. pmid:8250903
- View Article
- PubMed/NCBI
- Google Scholar
29. Ning LG, Shan G, Sun Z, Zhang F, Xu C, Lou X, et al. Quantitative Proteomic Analysis Reveals the Deregulation of Nicotinamide Adenine Dinucleotide Metabolism and CD38 in Inflammatory Bowel Disease. Biomed Res Int. 2019;2019. pmid:31179321
- View Article
- PubMed/NCBI
- Google Scholar
30. Schneider M, Schumacher V, Lischke T, Lücke K, Meyer-Schwesinger C, Velden J, et al. CD38 is expressed on inflammatory cells of the intestine and promotes intestinal inflammation. PLoS One. 2015;10: 1–16. pmid:25938500
- View Article
- PubMed/NCBI
- Google Scholar
31. van de Donk NWCJ, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunological Reviews. 2016. pp. 95–112. pmid:26864107
- View Article
- PubMed/NCBI
- Google Scholar
32. Tarragó MG, Chini CCS, Kanamori KS, Warner GM, Caride A, de Oliveira GC, et al. A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline. Cell Metab. 2018;27: 1081-1095.e10. pmid:29719225
- View Article
- PubMed/NCBI
- Google Scholar
33. Dölle C, Rack JGM, Ziegler M. NAD and ADP-ribose metabolism in mitochondria. FEBS J. 2013;280: 3530–3541. pmid:23617329
- View Article
- PubMed/NCBI
- Google Scholar
34. Litvak Y, Byndloss MX, Bäumler AJ. Colonocyte metabolism shapes the gut microbiota. Science (80-). 2018;362. pmid:30498100
- View Article
- PubMed/NCBI
- Google Scholar
35. Hughes ER, Winter MG, Duerkop BA, Spiga L, Furtado de Carvalho T, Zhu W, et al. Microbial Respiration and Formate Oxidation as Metabolic Signatures of Inflammation-Associated Dysbiosis. Cell Host Microbe. 2017;21: 208–219. pmid:28182951
- View Article
- PubMed/NCBI
- Google Scholar
36. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021. pp. 119–141. pmid:33353981
- View Article
- PubMed/NCBI
- Google Scholar
37. Gomes AP, Price NL, Ling AJY, Moslehi JJ, Montgomery MK, Rajman L, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155: 1624–1638. pmid:24360282
- View Article
- PubMed/NCBI
- Google Scholar
38. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Cantó C, et al. The NAD+/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell. 2013;154: 430. pmid:23870130
- View Article
- PubMed/NCBI
- Google Scholar
39. Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz SC, Suthammarak W, Gong G, et al. Mitochondrial complex i deficiency increases protein acetylation and accelerates heart failure. Cell Metab. 2013;18: 239–250. pmid:23931755
- View Article
- PubMed/NCBI
- Google Scholar
40. Camacho-Pereira J, Tarragó MG, Chini CCS, Nin V, Escande C, Warner GM, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23: 1127–1139. pmid:27304511
- View Article
- PubMed/NCBI
- Google Scholar
41. Barbosa MTP, Soares SM, Novak CM, Sinclair D, Levine JA, Aksoy P, et al. The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet‐induced obesity. FASEB J. 2007;21: 3629–3639. pmid:17585054
- View Article
- PubMed/NCBI
- Google Scholar
42. Fang EF, Scheibye-Knudsen M, Brace LE, Kassahun H, Sengupta T, Nilsen H, et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD +/SIRT1 reduction. Cell. 2014;157: 882–896. pmid:24813611
- View Article
- PubMed/NCBI
- Google Scholar
43. Starr AE, Deeke SA, Ning Z, Chiang CK, Zhang X, Mottawea W, et al. Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn’s disease from UC. Gut. 2017;66: 1573–1583. pmid:27216938
- View Article
- PubMed/NCBI
- Google Scholar
44. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an Adipocytokine with Proinflammatory and Immunomodulating Properties. J Immunol. 2007;178: 1748–1758. pmid:17237424
- View Article
- PubMed/NCBI
- Google Scholar
45. Larmonier CB, Shehab KW, Laubitz D, Jamwal DR, Ghishan FK, Kiela PR. Transcriptional reprogramming and resistance to colonic mucosal injury in poly (ADP-ribose) polymerase 1 (PARP1) deficient mice. J Biol Chem. 2016;291: 8918–8930. pmid:26912654
- View Article
- PubMed/NCBI
- Google Scholar
46. Popoff I, Jijon H, Monia B, Tavernini M, Ma M, McKay R, et al. Antisense oligonucleotides to poly(ADP-ribose) polymerase-2 ameliorate colitis in interleukin-10-deficient mice. J Pharmacol Exp Ther. 2002;303: 1145–1154. pmid:12438538
- View Article
- PubMed/NCBI
- Google Scholar
47. Lo Sasso G, Menzies KJ, Mottis A, Piersigilli A, Perino A, Yamamoto H, et al. SIRT2 deficiency modulates macrophage polarization and susceptibility to experimental colitis. PLoS One. 2014;9. pmid:25072851
- View Article
- PubMed/NCBI
- Google Scholar
48. Zhang Y, Wang X lan, Zhou M, Kang C, Lang H dong, Chen M ting, et al. Crosstalk between gut microbiota and Sirtuin-3 in colonic inflammation and tumorigenesis. Exp Mol Med. 2018;50. pmid:29650970
- View Article
- PubMed/NCBI
- Google Scholar
49. Wang F, Wang K, Xu W, Zhao S, Ye D, Wang Y, et al. SIRT5 Desuccinylates and Activates Pyruvate Kinase M2 to Block Macrophage IL-1β Production and to Prevent DSS-Induced Colitis in Mice. Cell Rep. 2017;19: 2331–2344. pmid:28614718
- View Article
- PubMed/NCBI
- Google Scholar
50. Liu F, Bu HF, Geng H, De Plaen IG, Gao C, Wang P, et al. Sirtuin-6 preserves R-spondin-1 expression and increases resistance of intestinal epithelium to injury in mice. Mol Med. 2017;23: 272–284. pmid:29387864
- View Article
- PubMed/NCBI
- Google Scholar
51. Caruso R, Marafini I, Franzè E, Stolfi C, Zorzi F, Monteleone I, et al. Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut. Mucosal Immunol. 2014;7: 1467–1479. pmid:24850427
- View Article
- PubMed/NCBI
- Google Scholar
52. Wellman AS, Metukuri MR, Kazgan N, Xu X, Xu Q, Ren NSX, et al. Intestinal Epithelial Sirtuin 1 Regulates Intestinal Inflammation During Aging in Mice by Altering the Intestinal Microbiota. Gastroenterology. 2017;153: 772–786. pmid:28552621
- View Article
- PubMed/NCBI
- Google Scholar
53. Sasso G Lo, Ryu D, Mouchiroud L, Fernando SC, Anderson CL, Katsyuba E, et al. Loss of Sirt1 Function Improves Intestinal Anti-Bacterial Defense and Protects from Colitis-Induced Colorectal Cancer. 2014;9: 1–10. pmid:25013930
- View Article
- PubMed/NCBI
- Google Scholar
54. German NJ, Haigis MC. Sirtuins and the Metabolic Hurdles in Cancer. Curr Biol. 2015;25: R569–R583. pmid:26126285
- View Article
- PubMed/NCBI
- Google Scholar

[ref1] 1. Roediger WEW. The Colonic Epithelium in Ulcerative Colitis: an Energy-Deficiency Disease? Lancet. 1980;316: 712–715.
View Article
Google Scholar

[2] View Article

[3] Google Scholar

[ref2] 2. Haberman Y, Karns R, Dexheimer PJ, Schirmer M, Somekh J, Jurickova I, et al. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun. 2019;10. pmid:30604764
View Article
PubMed/NCBI
Google Scholar

[5] View Article

[6] PubMed/NCBI

[7] Google Scholar

[ref3] 3. Smith SA, Ogawa SA, Chau L, Whelan KA, Hamilton KE, Chen J, et al. Mitochondrial dysfunction in inflammatory bowel disease alters intestinal epithelial metabolism of hepatic acylcarnitines. J Clin Invest. 2021;131. pmid:33141762
View Article
PubMed/NCBI
Google Scholar

[9] View Article

[10] PubMed/NCBI

[11] Google Scholar

[ref4] 4. Graham DB, Xavier RJ. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature. Springer US; 2020. pp. 527–539. pmid:32103191
View Article
PubMed/NCBI
Google Scholar

[13] View Article

[14] PubMed/NCBI

[15] Google Scholar

[ref5] 5. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491: 119–124. pmid:23128233
View Article
PubMed/NCBI
Google Scholar

[17] View Article

[18] PubMed/NCBI

[19] Google Scholar

[ref6] 6. Lahiri A, Hedl M, Yan J, Abraham C. Human LACC1 increases innate receptor-induced responses and a LACC1 disease-risk variant modulates these outcomes. Nat Commun. 2017;8: 1–13. pmid:28593945
View Article
PubMed/NCBI
Google Scholar

[21] View Article

[22] PubMed/NCBI

[23] Google Scholar

[ref7] 7. Muise AM, Xu W, Guo CH, Walters TD, Wolters VM, Fattouh R, et al. NADPH oxidase complex and IBD candidate gene studies: Identification of a rare variant in NCF2 that results in reduced binding to RAC2. Gut. 2012;61: 1028–1035. pmid:21900546
View Article
PubMed/NCBI
Google Scholar

[25] View Article

[26] PubMed/NCBI

[27] Google Scholar

[ref8] 8. Rivas MA, Beaudoin M, Gardet A, Stevens C, Sharma Y, Zhang CK, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet. 2011;43: 1066–1073. pmid:21983784
View Article
PubMed/NCBI
Google Scholar

[29] View Article

[30] PubMed/NCBI

[31] Google Scholar

[ref9] 9. Mishra P, Chan DC. Metabolic regulation of mitochondrial dynamics. J Cell Biol. 2016;212: 379–387. pmid:26858267
View Article
PubMed/NCBI
Google Scholar

[33] View Article

[34] PubMed/NCBI

[35] Google Scholar

[ref10] 10. Mehta MM, Weinberg SE, Chandel NS. Mitochondrial control of immunity: Beyond ATP. Nat Rev Immunol. 2017;17: 608–620. pmid:28669986
View Article
PubMed/NCBI
Google Scholar

[37] View Article

[38] PubMed/NCBI

[39] Google Scholar

[ref11] 11. Srivastava S. Emerging therapeutic roles for NAD + metabolism in mitochondrial and age-related disorders. Clin Transl Med. 2016;5: 25. pmid:27465020
View Article
PubMed/NCBI
Google Scholar

[41] View Article

[42] PubMed/NCBI

[43] Google Scholar

[ref12] 12. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu Rev Genet. 2005;39: 359–407. pmid:16285865
View Article
PubMed/NCBI
Google Scholar

[45] View Article

[46] PubMed/NCBI

[47] Google Scholar

[ref13] 13. Pang Z, Chong J, Li S, Xia J. Metaboanalystr 3.0: Toward an optimized workflow for global metabolomics. Metabolites. 2020;10. pmid:32392884
View Article
PubMed/NCBI
Google Scholar

[49] View Article

[50] PubMed/NCBI

[51] Google Scholar

[ref14] 14. Xia J, Wishart DS, Valencia A. MetPA: A web-based metabolomics tool for pathway analysis and visualization. Bioinformatics. 2011;27: 2342–2344. pmid:20628077
View Article
PubMed/NCBI
Google Scholar

[53] View Article

[54] PubMed/NCBI

[55] Google Scholar

[ref15] 15. Katsyuba E, Romani M, Hofer D, Auwerx J. NAD+ homeostasis in health and disease. Nature Metabolism. Springer US; 2020. pp. 9–31. pmid:32694684
View Article
PubMed/NCBI
Google Scholar

[57] View Article

[58] PubMed/NCBI

[59] Google Scholar

[ref16] 16. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science (80-). 2015;350: 1208–1213. pmid:26785480
View Article
PubMed/NCBI
Google Scholar

[61] View Article

[62] PubMed/NCBI

[63] Google Scholar

[ref17] 17. Kumar M, Garand M, Al Khodor S. Integrating omics for a better understanding of Inflammatory Bowel Disease: A step towards personalized medicine. J Transl Med. 2019;17: 1–13. pmid:31836022
View Article
PubMed/NCBI
Google Scholar

[65] View Article

[66] PubMed/NCBI

[67] Google Scholar

[ref18] 18. De Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: An integrated view of aetiology, pathogenesis and therapy. Nature Reviews Gastroenterology and Hepatology. 2017. pp. 739–749. pmid:28831186
View Article
PubMed/NCBI
Google Scholar

[69] View Article

[70] PubMed/NCBI

[71] Google Scholar

[ref19] 19. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4: 293–305. pmid:30531976
View Article
PubMed/NCBI
Google Scholar

[73] View Article

[74] PubMed/NCBI

[75] Google Scholar

[ref20] 20. Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569: 655–662. pmid:31142855
View Article
PubMed/NCBI
Google Scholar

[77] View Article

[78] PubMed/NCBI

[79] Google Scholar

[ref21] 21. Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V. Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017;11: 321–334. pmid:27609529
View Article
PubMed/NCBI
Google Scholar

[81] View Article

[82] PubMed/NCBI

[83] Google Scholar

[ref22] 22. Jansson J, Willing B, Lucio M, Fekete A, Dicksved J, Halfvarson J, et al. Metabolomics Reveals Metabolic Biomarkers of Crohn’s Disease. PLoS One. 2009;4: e6386. pmid:19636438
View Article
PubMed/NCBI
Google Scholar

[85] View Article

[86] PubMed/NCBI

[87] Google Scholar

[ref23] 23. Daniluk U, Daniluk J, Kucharski R, Kowalczyk T, Pietrowska K, Samczuk P, et al. Untargeted metabolomics and inflammatory markers profiling in children with Crohn’s disease and ulcerative colitis—A preliminary study. Inflamm Bowel Dis. 2019;25: 1120–1128. pmid:30772902
View Article
PubMed/NCBI
Google Scholar

[89] View Article

[90] PubMed/NCBI

[91] Google Scholar

[ref24] 24. Gerner RR, Klepsch V, Macheiner S, Arnhard K, Adolph TE, Grander C, et al. NAD metabolism fuels human and mouse intestinal inflammation. Gut. 2018;67: 1813–1823. pmid:28877980
View Article
PubMed/NCBI
Google Scholar

[93] View Article

[94] PubMed/NCBI

[95] Google Scholar

[ref25] 25. Colombo G, Clemente N, Zito A, Bracci C, Colombo FS, Sangaletti S, et al. Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. J Mol Med. 2020;98: 595–612. pmid:32338310
View Article
PubMed/NCBI
Google Scholar

[97] View Article

[98] PubMed/NCBI

[99] Google Scholar

[ref26] 26. Diab J, Hansen T, Goll R, Stenlund H, Jensen E, Moritz T, et al. Mucosal metabolomic profiling and pathway analysis reveal the metabolic signature of ulcerative colitis. Metabolites. 2019;9: 1–15. pmid:31783598
View Article
PubMed/NCBI
Google Scholar

[101] View Article

[102] PubMed/NCBI

[103] Google Scholar

[ref27] 27. Hogan KA, Chini CCS, Chini EN. The Multi-faceted Ecto-enzyme CD38: Roles in immunomodulation, cancer, aging, and metabolic diseases. Front Immunol. 2019;10: 1–12. pmid:31214171
View Article
PubMed/NCBI
Google Scholar

[105] View Article

[106] PubMed/NCBI

[107] Google Scholar

[ref28] 28. Zocchi E, Franco L, Guida L, Benatti U, Bargellesi A, Malavasi F, et al. A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. Biochem Biophys Res Commun. 1993;196: 1459–1465. pmid:8250903
View Article
PubMed/NCBI
Google Scholar

[109] View Article

[110] PubMed/NCBI

[111] Google Scholar

[ref29] 29. Ning LG, Shan G, Sun Z, Zhang F, Xu C, Lou X, et al. Quantitative Proteomic Analysis Reveals the Deregulation of Nicotinamide Adenine Dinucleotide Metabolism and CD38 in Inflammatory Bowel Disease. Biomed Res Int. 2019;2019. pmid:31179321
View Article
PubMed/NCBI
Google Scholar

[113] View Article

[114] PubMed/NCBI

[115] Google Scholar

[ref30] 30. Schneider M, Schumacher V, Lischke T, Lücke K, Meyer-Schwesinger C, Velden J, et al. CD38 is expressed on inflammatory cells of the intestine and promotes intestinal inflammation. PLoS One. 2015;10: 1–16. pmid:25938500
View Article
PubMed/NCBI
Google Scholar

[117] View Article

[118] PubMed/NCBI

[119] Google Scholar

[ref31] 31. van de Donk NWCJ, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunological Reviews. 2016. pp. 95–112. pmid:26864107
View Article
PubMed/NCBI
Google Scholar

[121] View Article

[122] PubMed/NCBI

[123] Google Scholar

[ref32] 32. Tarragó MG, Chini CCS, Kanamori KS, Warner GM, Caride A, de Oliveira GC, et al. A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline. Cell Metab. 2018;27: 1081-1095.e10. pmid:29719225
View Article
PubMed/NCBI
Google Scholar

[125] View Article

[126] PubMed/NCBI

[127] Google Scholar

[ref33] 33. Dölle C, Rack JGM, Ziegler M. NAD and ADP-ribose metabolism in mitochondria. FEBS J. 2013;280: 3530–3541. pmid:23617329
View Article
PubMed/NCBI
Google Scholar

[129] View Article

[130] PubMed/NCBI

[131] Google Scholar

[ref34] 34. Litvak Y, Byndloss MX, Bäumler AJ. Colonocyte metabolism shapes the gut microbiota. Science (80-). 2018;362. pmid:30498100
View Article
PubMed/NCBI
Google Scholar

[133] View Article

[134] PubMed/NCBI

[135] Google Scholar

[ref35] 35. Hughes ER, Winter MG, Duerkop BA, Spiga L, Furtado de Carvalho T, Zhu W, et al. Microbial Respiration and Formate Oxidation as Metabolic Signatures of Inflammation-Associated Dysbiosis. Cell Host Microbe. 2017;21: 208–219. pmid:28182951
View Article
PubMed/NCBI
Google Scholar

[137] View Article

[138] PubMed/NCBI

[139] Google Scholar

[ref36] 36. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021. pp. 119–141. pmid:33353981
View Article
PubMed/NCBI
Google Scholar

[141] View Article

[142] PubMed/NCBI

[143] Google Scholar

[ref37] 37. Gomes AP, Price NL, Ling AJY, Moslehi JJ, Montgomery MK, Rajman L, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155: 1624–1638. pmid:24360282
View Article
PubMed/NCBI
Google Scholar

[145] View Article

[146] PubMed/NCBI

[147] Google Scholar

[ref38] 38. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Cantó C, et al. The NAD+/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell. 2013;154: 430. pmid:23870130
View Article
PubMed/NCBI
Google Scholar

[149] View Article

[150] PubMed/NCBI

[151] Google Scholar

[ref39] 39. Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz SC, Suthammarak W, Gong G, et al. Mitochondrial complex i deficiency increases protein acetylation and accelerates heart failure. Cell Metab. 2013;18: 239–250. pmid:23931755
View Article
PubMed/NCBI
Google Scholar

[153] View Article

[154] PubMed/NCBI

[155] Google Scholar

[ref40] 40. Camacho-Pereira J, Tarragó MG, Chini CCS, Nin V, Escande C, Warner GM, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23: 1127–1139. pmid:27304511
View Article
PubMed/NCBI
Google Scholar

[157] View Article

[158] PubMed/NCBI

[159] Google Scholar

[ref41] 41. Barbosa MTP, Soares SM, Novak CM, Sinclair D, Levine JA, Aksoy P, et al. The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet‐induced obesity. FASEB J. 2007;21: 3629–3639. pmid:17585054
View Article
PubMed/NCBI
Google Scholar

[161] View Article

[162] PubMed/NCBI

[163] Google Scholar

[ref42] 42. Fang EF, Scheibye-Knudsen M, Brace LE, Kassahun H, Sengupta T, Nilsen H, et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD +/SIRT1 reduction. Cell. 2014;157: 882–896. pmid:24813611
View Article
PubMed/NCBI
Google Scholar

[165] View Article

[166] PubMed/NCBI

[167] Google Scholar

[ref43] 43. Starr AE, Deeke SA, Ning Z, Chiang CK, Zhang X, Mottawea W, et al. Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn’s disease from UC. Gut. 2017;66: 1573–1583. pmid:27216938
View Article
PubMed/NCBI
Google Scholar

[169] View Article

[170] PubMed/NCBI

[171] Google Scholar

[ref44] 44. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an Adipocytokine with Proinflammatory and Immunomodulating Properties. J Immunol. 2007;178: 1748–1758. pmid:17237424
View Article
PubMed/NCBI
Google Scholar

[173] View Article

[174] PubMed/NCBI

[175] Google Scholar

[ref45] 45. Larmonier CB, Shehab KW, Laubitz D, Jamwal DR, Ghishan FK, Kiela PR. Transcriptional reprogramming and resistance to colonic mucosal injury in poly (ADP-ribose) polymerase 1 (PARP1) deficient mice. J Biol Chem. 2016;291: 8918–8930. pmid:26912654
View Article
PubMed/NCBI
Google Scholar

[177] View Article

[178] PubMed/NCBI

[179] Google Scholar

[ref46] 46. Popoff I, Jijon H, Monia B, Tavernini M, Ma M, McKay R, et al. Antisense oligonucleotides to poly(ADP-ribose) polymerase-2 ameliorate colitis in interleukin-10-deficient mice. J Pharmacol Exp Ther. 2002;303: 1145–1154. pmid:12438538
View Article
PubMed/NCBI
Google Scholar

[181] View Article

[182] PubMed/NCBI

[183] Google Scholar

[ref47] 47. Lo Sasso G, Menzies KJ, Mottis A, Piersigilli A, Perino A, Yamamoto H, et al. SIRT2 deficiency modulates macrophage polarization and susceptibility to experimental colitis. PLoS One. 2014;9. pmid:25072851
View Article
PubMed/NCBI
Google Scholar

[185] View Article

[186] PubMed/NCBI

[187] Google Scholar

[ref48] 48. Zhang Y, Wang X lan, Zhou M, Kang C, Lang H dong, Chen M ting, et al. Crosstalk between gut microbiota and Sirtuin-3 in colonic inflammation and tumorigenesis. Exp Mol Med. 2018;50. pmid:29650970
View Article
PubMed/NCBI
Google Scholar

[189] View Article

[190] PubMed/NCBI

[191] Google Scholar

[ref49] 49. Wang F, Wang K, Xu W, Zhao S, Ye D, Wang Y, et al. SIRT5 Desuccinylates and Activates Pyruvate Kinase M2 to Block Macrophage IL-1β Production and to Prevent DSS-Induced Colitis in Mice. Cell Rep. 2017;19: 2331–2344. pmid:28614718
View Article
PubMed/NCBI
Google Scholar

[193] View Article

[194] PubMed/NCBI

[195] Google Scholar

[ref50] 50. Liu F, Bu HF, Geng H, De Plaen IG, Gao C, Wang P, et al. Sirtuin-6 preserves R-spondin-1 expression and increases resistance of intestinal epithelium to injury in mice. Mol Med. 2017;23: 272–284. pmid:29387864
View Article
PubMed/NCBI
Google Scholar

[197] View Article

[198] PubMed/NCBI

[199] Google Scholar

[ref51] 51. Caruso R, Marafini I, Franzè E, Stolfi C, Zorzi F, Monteleone I, et al. Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut. Mucosal Immunol. 2014;7: 1467–1479. pmid:24850427
View Article
PubMed/NCBI
Google Scholar

[201] View Article

[202] PubMed/NCBI

[203] Google Scholar

[ref52] 52. Wellman AS, Metukuri MR, Kazgan N, Xu X, Xu Q, Ren NSX, et al. Intestinal Epithelial Sirtuin 1 Regulates Intestinal Inflammation During Aging in Mice by Altering the Intestinal Microbiota. Gastroenterology. 2017;153: 772–786. pmid:28552621
View Article
PubMed/NCBI
Google Scholar

[205] View Article

[206] PubMed/NCBI

[207] Google Scholar

[ref53] 53. Sasso G Lo, Ryu D, Mouchiroud L, Fernando SC, Anderson CL, Katsyuba E, et al. Loss of Sirt1 Function Improves Intestinal Anti-Bacterial Defense and Protects from Colitis-Induced Colorectal Cancer. 2014;9: 1–10. pmid:25013930
View Article
PubMed/NCBI
Google Scholar

[209] View Article

[210] PubMed/NCBI

[211] Google Scholar

[ref54] 54. German NJ, Haigis MC. Sirtuins and the Metabolic Hurdles in Cancer. Curr Biol. 2015;25: R569–R583. pmid:26126285
View Article
PubMed/NCBI
Google Scholar

[213] View Article

[214] PubMed/NCBI

[215] Google Scholar

Figures

Abstract

Introduction

Materials and methods

Study design and sample collection

Metabolomics–Sample preparation

Metabolomics–data analysis

Mitochondrial electron microscopy–sample preparation, data collection, and analysis

Results

Intestinal metabolomic profiles cluster primarily by inflammation state

NAD+ metabolism is dysregulated in inflamed tissue

Intestinal NAD+/NAM ratios predict inflammation but not diagnosis

UC patients display altered mitochondrial morphology in the intestine

Discussion

Supporting information

S1 Fig.

S2 Fig. Graphs of other metabolites differentially regulated as in Fig 1E but not shown in Fig 2C–2E.

S3 Fig. NAD, NAM and ADPr from Fig 2C–2E, with further separation of uninflamed samples into controls and UC uninflamed.

S4 Fig. PCA Analyses focusing on PC3 and PC4.

S5 Fig. Quantitation of the EM micrographs as in Fig 4, but with samples stratified by inflammation.

S1 Table. Patient demographics for the EM study, showing age (mean ± S.D.), gender, BMI (mean ± S.D.), biopsy location, duration of disease (mean ± S.D.), disease activity, extent of disease (mean ± S.D.), and treatment demographics.

Acknowledgments

References

NAD⁺ metabolism is dysregulated in inflamed tissue

Intestinal NAD⁺/NAM ratios predict inflammation but not diagnosis